News

We’re Making Waves

Water-soluable Vitamin K2 MK 7 Ingredient Eases Formulation

A novel, new water-soluable vitamin K2 MK-7 ingredients makes inclusion in aqueous products easier, without requiring extra processing steps such as microencapsulation or emulsification. Read more

Pharma-grade vitamin K ingredient enters supplements market

Viridis BioPharma/Synergia Life Sciences has announced a 10-fold expansion of its vitamin K production facility, a move which sees the company’s pharmaceutical-grade ingredient’s availability extended to all dietary supplements. Read more

WIPO assigns patent to Viridis Biopharma for "Method of use of Vitamin K as energy enhancer in diverse disease states" (Indian Inventors)

According to the abstract posted by the World Intellectual Property Organization: "The invention relates to Vitamin K, its derivatives and combinations to increase the energy levels in diverse disease states and life style disorders, which are characterized by low energy level due to inadequate VO 2 max and pO 2 and low availability of ATP.” Read more

Viridis Biopharma receives approval to manufacture, market Nimbus® antimicrobial technology in India

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that its proprietary NIMBUS® antimicrobial technology has been approved for manufacture, marketing and sale in India. Viridis BioPharma, an India-based manufacturer and marketer of medical devices, received approval by the Food and Drug Administration (FDA) of India to manufacture and market gauze wound dressings that incorporate NIMBUS® antimicrobial technology. Read more

Quick-Med Expands NIMBUS(R) Technology Into Advanced Wound Care Dressings

GAINESVILLE, Fla., Feb. 14, 2012 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has amended the license previously granted to Viridis BioPharma Read more